Cargando…
Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study
BACKGROUND: Idiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid therapy, all of which can lead to metabolism disturbances, atherogenesis, and increased cardiovascular (CV) risk. The aim of this study was to assess the CV risk in II...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118331/ https://www.ncbi.nlm.nih.gov/pubmed/35602501 http://dx.doi.org/10.3389/fmed.2022.861419 |
_version_ | 1784710472484782080 |
---|---|
author | Oreska, Sabina Storkanova, Hana Kudlicka, Jaroslav Tuka, Vladimir Mikes, Ondrej Krupickova, Zdislava Satny, Martin Chytilova, Eva Kvasnicka, Jan Spiritovic, Maja Hermankova, Barbora Cesak, Petr Rybar, Marian Pavelka, Karel Senolt, Ladislav Mann, Herman Vencovsky, Jiri Vrablik, Michal Tomcik, Michal |
author_facet | Oreska, Sabina Storkanova, Hana Kudlicka, Jaroslav Tuka, Vladimir Mikes, Ondrej Krupickova, Zdislava Satny, Martin Chytilova, Eva Kvasnicka, Jan Spiritovic, Maja Hermankova, Barbora Cesak, Petr Rybar, Marian Pavelka, Karel Senolt, Ladislav Mann, Herman Vencovsky, Jiri Vrablik, Michal Tomcik, Michal |
author_sort | Oreska, Sabina |
collection | PubMed |
description | BACKGROUND: Idiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid therapy, all of which can lead to metabolism disturbances, atherogenesis, and increased cardiovascular (CV) risk. The aim of this study was to assess the CV risk in IIM patients and healthy controls (HC), and its association with disease-specific features. METHODS: Thirty nine patients with IIM (32 females; mean age 56; mean disease duration 4.8 years; dermatomyositis: n = 16, polymyositis: n = 7, immune-mediated necrotizing myopathy: n = 8, anti-synthetase syndrome: n = 8) and 39 age-/sex-matched HC (32 females, mean age 56) without rheumatic diseases were included. In both groups, subjects with a history of CV disease (angina pectoris, myocardial infarction, cerebrovascular, and peripheral arterial vascular events) were excluded. Muscle involvement, disease activity, and tissue damage were evaluated (Manual Muscle Test-8, Myositis Intention to Treat Activity Index, Myositis Damage Index). Comorbidities and current treatment were recorded. All participants underwent examinations of carotid intima-media thickness (CIMT), pulse wave velocity (PWV), ankle-brachial index (ABI), and body composition (by densitometry and bioelectric impedance). The risk of fatal CV events was evaluated by the Systematic COronary Risk Evaluation (SCORE, charts for the European population) and its modifications. RESULTS: Compared to HC, there was no significant difference in IIM patients regarding blood pressure, ABI, PWV, CIMT, and the risk of fatal CV events by SCORE or SCORE2, or subclinical atherosclerosis (CIMT, carotid plaques, ABI, and PWV). The calculated CV risk scores by SCORE, SCORE2, and SCORE multiplied by the coefficient 1.5 (mSCORE) were reclassified according to the results of carotid plaque presence and CIMT; however, none of them was demonstrated to be significantly more accurate. Other significant predictors of CV risk in IIM patients included age, disease duration and activity, systemic inflammation, lipid profile, lean body mass, and blood pressure. CONCLUSIONS: No significant differences in CV risk factors between our IIM patients and HC were observed. However, in IIM, CV risk was associated with age, disease duration, duration of glucocorticoid therapy, lipid profile, and body composition. None of the currently available scoring tools (SCORE, SCORE2, mSCORE) used in this study seems more accurate in estimating CV risk in IIM. |
format | Online Article Text |
id | pubmed-9118331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91183312022-05-20 Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study Oreska, Sabina Storkanova, Hana Kudlicka, Jaroslav Tuka, Vladimir Mikes, Ondrej Krupickova, Zdislava Satny, Martin Chytilova, Eva Kvasnicka, Jan Spiritovic, Maja Hermankova, Barbora Cesak, Petr Rybar, Marian Pavelka, Karel Senolt, Ladislav Mann, Herman Vencovsky, Jiri Vrablik, Michal Tomcik, Michal Front Med (Lausanne) Medicine BACKGROUND: Idiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid therapy, all of which can lead to metabolism disturbances, atherogenesis, and increased cardiovascular (CV) risk. The aim of this study was to assess the CV risk in IIM patients and healthy controls (HC), and its association with disease-specific features. METHODS: Thirty nine patients with IIM (32 females; mean age 56; mean disease duration 4.8 years; dermatomyositis: n = 16, polymyositis: n = 7, immune-mediated necrotizing myopathy: n = 8, anti-synthetase syndrome: n = 8) and 39 age-/sex-matched HC (32 females, mean age 56) without rheumatic diseases were included. In both groups, subjects with a history of CV disease (angina pectoris, myocardial infarction, cerebrovascular, and peripheral arterial vascular events) were excluded. Muscle involvement, disease activity, and tissue damage were evaluated (Manual Muscle Test-8, Myositis Intention to Treat Activity Index, Myositis Damage Index). Comorbidities and current treatment were recorded. All participants underwent examinations of carotid intima-media thickness (CIMT), pulse wave velocity (PWV), ankle-brachial index (ABI), and body composition (by densitometry and bioelectric impedance). The risk of fatal CV events was evaluated by the Systematic COronary Risk Evaluation (SCORE, charts for the European population) and its modifications. RESULTS: Compared to HC, there was no significant difference in IIM patients regarding blood pressure, ABI, PWV, CIMT, and the risk of fatal CV events by SCORE or SCORE2, or subclinical atherosclerosis (CIMT, carotid plaques, ABI, and PWV). The calculated CV risk scores by SCORE, SCORE2, and SCORE multiplied by the coefficient 1.5 (mSCORE) were reclassified according to the results of carotid plaque presence and CIMT; however, none of them was demonstrated to be significantly more accurate. Other significant predictors of CV risk in IIM patients included age, disease duration and activity, systemic inflammation, lipid profile, lean body mass, and blood pressure. CONCLUSIONS: No significant differences in CV risk factors between our IIM patients and HC were observed. However, in IIM, CV risk was associated with age, disease duration, duration of glucocorticoid therapy, lipid profile, and body composition. None of the currently available scoring tools (SCORE, SCORE2, mSCORE) used in this study seems more accurate in estimating CV risk in IIM. Frontiers Media S.A. 2022-05-03 /pmc/articles/PMC9118331/ /pubmed/35602501 http://dx.doi.org/10.3389/fmed.2022.861419 Text en Copyright © 2022 Oreska, Storkanova, Kudlicka, Tuka, Mikes, Krupickova, Satny, Chytilova, Kvasnicka, Spiritovic, Hermankova, Cesak, Rybar, Pavelka, Senolt, Mann, Vencovsky, Vrablik and Tomcik. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Oreska, Sabina Storkanova, Hana Kudlicka, Jaroslav Tuka, Vladimir Mikes, Ondrej Krupickova, Zdislava Satny, Martin Chytilova, Eva Kvasnicka, Jan Spiritovic, Maja Hermankova, Barbora Cesak, Petr Rybar, Marian Pavelka, Karel Senolt, Ladislav Mann, Herman Vencovsky, Jiri Vrablik, Michal Tomcik, Michal Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study |
title | Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study |
title_full | Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study |
title_fullStr | Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study |
title_full_unstemmed | Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study |
title_short | Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study |
title_sort | cardiovascular risk in myositis patients compared to the general population: preliminary data from a single-center cross-sectional study |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118331/ https://www.ncbi.nlm.nih.gov/pubmed/35602501 http://dx.doi.org/10.3389/fmed.2022.861419 |
work_keys_str_mv | AT oreskasabina cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT storkanovahana cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT kudlickajaroslav cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT tukavladimir cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT mikesondrej cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT krupickovazdislava cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT satnymartin cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT chytilovaeva cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT kvasnickajan cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT spiritovicmaja cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT hermankovabarbora cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT cesakpetr cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT rybarmarian cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT pavelkakarel cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT senoltladislav cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT mannherman cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT vencovskyjiri cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT vrablikmichal cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT tomcikmichal cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy |